Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

Cyclopharm begins nuclear imaging trial to detect respiratory diseases

Cyclopharm (ASX:CYC) is commencing a new study to assess lung function in real time, using its radioactive functional ventilation tracer called Technegas.

Cyclopharm makes progress on U.S. clinical trial

Technegas generators produce a gas which is inhaled by patients before taking scans, to assist in the detection of pulmonary embolism. The U.S. trial was set out to determine inter-reader and intra-reader variability for Xenon-133 gas, the only existing FDA approved nuclear medicine ventilation imaging agent in the U.S. This step was essential in establishing the number of patients required for the next stage in the clinical trial program.

Cyclopharm Ltd expands lung imaging diagnostic in North America

Cyclopharm Ltd (ASX:CYC) is a radiopharmaceutical company and which manufactures and distributes nuclear medicine lung ventilation imaging.

Managing Director's Report


Results of Annual General Meeting


Board Changes / Appendix 3Z


Appendix 4G


Annual Report to shareholders


Preliminary Final Report